TrialPharmacoEconomics2016

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Abdullah Pandor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.